Global Artificial Heart Market is valued at approximately USD XXX million in 2021 and is anticipated to grow with a healthy growth rate of more than 15.4% over the forecast period 2022-2028. A surgically implanted pump is referred to as an artificial heart or entire artificial heart and is used to substitute diseased or damaged heart ventricles and provide circulation. The heart's ventricles transport blood from the chambers to the lungs and other organs. The implanted pumps are managed by machines outside the body, assisting blood flow to and from the heart. The factors propelling the market growth are technological advancements and growing burden of Cardiovascular diseases. According to a report by the British Heart Foundation, January 2022, there are around 7.6 million individuals in the UK who have heart disease, and this causes up to 160,000 deaths annually. Cardiovascular diseases cause an average of 460 deaths each day, or one fatality every three minutes, in the United Kingdom (CVDs). The category is also expected to increase as a result of the introduction of new products and ongoing government support. A China-developed "artificial heart" for severe heart failure, for instance, received marketing approval from China's National Medical Products Administration in July 2022. The "heart" is a left ventricular assist device that is implantable and powered by ferrofluids. Furthermore, increase in the geriatric population propels the market opportunities in the upcoming years. However, high cost of Artificial Heart and related surgery and strict regulatory scenario impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Artificial Heart Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the global market revenue share owing to growing burden of cardiovascular diseases and rising adoption of technologies. However, Asia Pacific region is expected to be the market growth due to rapid adaptation of healthcare technology in the region.

Major market players included in this report are:

ReinHeart TAH GmbH

SynCardia Systems, LLC

Calon Cardio-Technology Ltd

Abiomed

CryoLife, Inc

BiVACOR Inc.

Jarvik Heart, Inc.

Abbott

Carmat

Berlin Heart Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Application offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Ventricular Assist Device

Total Artificial Heart

Heart-Lung Machine

Others

By Power Source:

Internal Battery

External Battery

By End User:

Hospitals and Clinics

Specialty Clinics

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Artificial Heart Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors